VCEL
Vericel Corp OrdNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.81B
P/E Ratio
111.16
EPS
$0.32
Beta
1.21
52W High
$45.97
52W Low
$28.95
50-Day MA
$34.07
200-Day MA
$35.67
Dividend Yield
—
Profit Margin
5.98%
Forward P/E
95.24
PEG Ratio
0.00
About Vericel Corp Ord
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cell therapies for the sports medicine and severe burn care markets in the United States. The company is headquartered in Cambridge, Massachusetts.
Fundamentals
| Revenue (TTM) | $276.26M |
| Gross Profit (TTM) | $205.60M |
| EBITDA | $22.59M |
| Operating Margin | 24.10% |
| Return on Equity | 5.11% |
| Return on Assets | 1.50% |
| Revenue/Share (TTM) | $5.49 |
| Book Value | $7.01 |
| Price-to-Book | 5.11 |
| Price-to-Sales (TTM) | 6.56 |
| EV/Revenue | 6.41 |
| EV/EBITDA | 59.90 |
| Quarterly Earnings Growth (YoY) | 18.90% |
| Quarterly Revenue Growth (YoY) | 23.30% |
| Shares Outstanding | $50.93M |
| Float | $47.59M |
| % Insiders | 1.47% |
| % Institutions | 111.56% |
Historical Volatility
HV 10-Day
67.96%
HV 20-Day
54.97%
HV 30-Day
55.93%
HV 60-Day
47.26%
HV Rank
71.0%
Volatility is currently expanding
Analyst Ratings
Consensus ($54.57 target)
7
Buy1
HoldMore HEALTHCARE Stocks
Data last updated: 5/2/2026